Business and Finance

Latest annual Progressions report highlights the shift to healthy behaviors

Patient office visits, prescription usage continued to decline

Covis Pharmaceuticals' business model is to acquire distribution rights to low-volume drugs

Applying a consistent framework to choose locations can help optimize R&D and drive cost reduction for pharmaceutical companies of all sizes

Pharmaceutical Commerce sat down with Chris Smith, president and COO; here's what he had to say.

Buys marketing rights to networks of independent pharmacies for C$920 million

White paper points out the drop in pipeline performance; suggests a new direction is necessary

Taking a market-by-market approach to maximizing value after loss of exclusivity

Small changes in contract terms can have large consequences in net revenue

Life sciences CFOs can address growing cost pressures through decision support centralization

Recognizing the realities of how new product launches enter the market

Regional pharmacy benefit manager is on a growth curve

CLM Matrix system exploits Microsoft SharePoint platform

Generics claim 78% of US market; prescriptions dispensed were up slightly, but doctor visits declined in 2010

Cost dominates the payer and physician perspective, manufacturers look to outcomes, while patients see little value in outcomes

The recent acquisition of US Oncology by McKesson highlights the rising importance of the distributor-led networks

Overestimating product reserves as loss of exclusivity (LoE) approaches can be a $75-million mistake

Once reserved for uninsured, many patient-assistance programs have evolved to meet the needs of the under-insured. On the horizon: the potential effects of healthcare reform law

US growth remains off the global pace, market will expand by 3-5%, to $320-330 billion

Annual polling and analysis for the Dow Jones Sustainability Index lists 20 healthcare companies

The count of independent pharmacies is growing, belying past pessimism

The 7th Annual Model N survey shows that industry is struggling with the growing complexity of contracts and pricing for managed care and government programs